Prediction of metabolic drug clearance in humans:In vitro–in vivoextrapolationvsallometric scaling
The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Abstract
Previously in vitro–in vivo extrapolation (IVIVE) with the Simcyp Clearance and Interaction Simulator® has been used to predict the clearance of 15 clinically used drugs in humans. The criteria for the selection of the drugs were that they are used as probes for the activity of specific cytochromes P450 (CYPs) or have a single CYP isoform as the major or sole contributor to their metabolism and that they do not exhibit non-linear kinetics in vivo. Where data were available for the clearance of the drugs in at least three animal species, the predictions from IVIVE have now been compared with those based on allometric scaling (AS). Adequate data were available for estimating oral clearance (CLp.o.) in 9 cases (alprazolam, sildenafil, caffeine, clozapine, cyclosporine, dextromethorphan, midazolam, omeprazole and tolbutamide) and intravenous clearance in 6 cases (CLi.v.) (cyclosporine, diclofenac, midazolam, omeprazole, theophylline and tolterodine). AS predictions were based on five different methods: (1) simple allometry (clearance versus body weight); (2) correction for maximum life-span potential (CL × MLP); (3) correction for brain weight (CL × BrW); (4) the use of body surface area; and (5) the rule of exponents. A prediction accuracy was indicated by mean-fold error and the Pearson product moment correlation coefficient. Predictions were considered successful if the mean-fold error was ≤2. IVIVE predictions were accurate in 14 of 15 cases (mean-fold error range: 1.02–4.00). All five AS methods were accurate in 13, 11, 10, 10 and 14 cases, respectively. However, in some cases the error of AS exceeded fivefold. On the basis of the current results, IVIVE is more reliable than AS in predicting human clearance values for drugs mainly metabolized by CYP450 enzymes. This suggests that the place of AS methods in pre-clinical drug development warrants further scrutiny.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“however, the apparent universality of the allometric exponent can obscure compound-specific ADME determinants that differ markedly across species [6,14].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [14]
In the citing paper
“Allometry provides a first approximation, but ADME processes are fundamentally pathway- and species-dependent, and a visually compelling log–log line across a narrow species panel may still catastrophically mispredict human pharmacokinetics [6,14,21].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [14]
In the citing paper
“In such cases, IVIVE incorporating transporter kinetics, or mechanistic PBPK models with explicit sinusoidal uptake modules, provides superior predictions [14,26,42].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [14]
In the citing paper
“For drugs where hepatic uptake via organic anion-transporting polypeptides (OATPs) is rate-limiting, simple allometric scaling of total clearance may fail because transporter expression levels and substrate specificities differ between preclinical species and humans.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [14]
In the citing paper
“consensus reference values continue to evolve [14,42]”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [14]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
Drug Metabolism and Disposition
(2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12259_4 · Cited by 2,515
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648 · cited 1×
“Boxenbaum (1982, 1984) suggested the incorporation of maximum lifespan potential (MLP) as a correction factor to normalize for the metabolic capacity of different species.”
BackgroundThummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., & Wilkinson, G. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90177-0 · Cited by 617
Effect of Age, Gender, and Obesity on Midazolam Kinetics
Greenblatt, D. J., Abernethy, D. R., Locniskar, A., Harmatz, J. S., Limjuco, R. A., & Shader, R. I. (1984) · Anesthesiology · doi:10.1097/00000542-198407000-00006 · Cited by 583
The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism
Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z.-Y., Kaminsky, L. S., Shenfleld, G. M., Miners, J. O., Birkett, D. J., & Goldstein, J. A. (1996) · Pharmacogenetics · doi:10.1097/00008571-199608000-00007 · Cited by 582
Johnson, T. N., Rostami-Hodjegan, A., & Tucker, G. T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645090-00005 · Cited by 530 · cited 1×
“A clear application of this would be in the assessment of genetic differences in ethnic groups, as indicated by Inoue et al. (2006), and in the evaluation of age related changes in paediatrics, particularly in neonates and infants, as shown by Johnson et al. (2006).”
BackgroundSelf-citationEffect of Age, Gender, and Obesity on Midazolam Kinetics
Greenblatt, D. J., Abernethy, D. R., Locniskar, A., et al. (1984) · Anesthesiology · doi:10.1097/00000542-198461010-00006 · Cited by 461
Christopher Gorski, J., Hall, S. D., Jones, D. R., & VandenBranden, M. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90543-6 · Cited by 395
Research works printed but not linked: 18
- Amchin J, 1998, Psychopharmacology Bulletin, 34, 211
- Bae HY, 2002, Research Communications in Molecular Pathology and Pharmacology, 111, 237
- Hamaoka N, 1999, Clinical Pharmacology and Therapy, 66, 110, 10.1053/cp.1999.v66.100038001 · doi:10.1053/cp.1999.v66.100038001 · Paper page
- Ibrahim A, 2002, Anesthesia and Analgesics, 95, 667, 10.1213/00000539-200209000-00032 · doi:10.1213/00000539-200209000-00032
- Johnson TN, 2006, Clinical Pharmacokinetics (in press)
- Karam WG, 1996, Drug Metabolism and Disposition, 24, 1081
- Keldenich J, 2004, Technologies, 1, 389
- Knodell RG, 1987, Journal of Pharmacology and Experimental Therapy, 241, 1112
- Linnet K, 1997, Drug Metabolism and Disposition, 25, 1379
- Pahlman I, 2001, Arzneimittelforschung, 51, 134
- Postlind H, 1998, Drug Metabolism and Disposition, 26, 289
- Rane A, 1977, Journal of Pharmacology and Experimental Therapy, 200, 420
- Sangalli L, 1988, Drug Metabolism and Disposition, 16, 749
- Tantcheva-Poor I, 1999, Pharmacogenetics, 9, 131
- Tsunoda SM, 2001, Clinical Pharmacology and Therapy, 70, 462, 10.1016/S0009-9236(01)70992-7 · doi:10.1016/s0009-9236(01)70992-7
- Watanabe K, 2002, Acta Medica Okayama, 56, 19
- Yu A, 2001, Drug Metabolism and Disposition, 29, 1362
- Zeng YL, 1986, Yao Xue Xue Bao, 21, 566
Cited by
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
Jones, H., & Rowland‐Yeo, K. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.41 · Cited by 626
Self-citationThe Simcyp ® Population-based ADME Simulator
Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., & Rostami-Hodjegan, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802691074 · Cited by 533
“Its utility is attested by an increasing number of both in-house and independent publications [9,15,16,21-30] .”
BackgroundSelf-citationSimulation and prediction of in vivo drug metabolism in human populations from in vitro data
Rostami-Hodjegan, A., & Tucker, G. T. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2173 · Cited by 530
Incorporating Human Dosimetry and Exposure into High-Throughput In Vitro Toxicity Screening
Rotroff, D. M., Wetmore, B. A., Dix, D. J., Ferguson, S. S., Clewell, H. J., Houck, K. A., LeCluyse, E. L., Andersen, M. E., Judson, R. S., Smith, C. M., et al. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq220 · Cited by 250
“The metabolic clearance and plasma protein binding measure- ments were used together with in vitro-to-in vivo extrapolation modeling to predict the PK behavior of the chemicals at steady state (Shiran et al., 2006).”
MethodApplications of minimal physiologically-based pharmacokinetic models
Cao, Y., & Jusko, W. J. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9280-2 · Cited by 202
“Tissue intrinsic clearances are easier to match to in vitro observations and have higher scaling potential to other species than systemic clearance [55].”
Metadata
- Authors
- Shiran, M. R., Proctor, N. J., Howgate, E. M., Rowland-Yeo, K., Tucker, G. T., & Rostami-Hodjegan, A.
- Affiliations
- Simcyp (United Kingdom) (GB)
- Royal Hallamshire Hospital (GB)
- Venue
- Xenobiotica
- Publisher
- Informa UK Limited
- Published
- 2006-07
- Volume
- 36
- Issue
- 7
- Pages
- 567-580
- ISSN
- 0049-8254 (ISSN-L)
- 1366-5928
- OpenAlex
- W2158185292
- Cited by
- 89
- References
- 122
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 1 · 2016: 3 · 2015: 5 · 2014: 3 · 2013: 2 · 2012: 10
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Xenobiotica (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Dr Hadwen Trust for Humane Research
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- in vitro-in vivo extrapolation, allometric scaling, cytochrome P450, oral clearance, body surface area, preclinical drug development, alprazolam, sildenafil, caffeine, clozapine, cyclosporine, dextromethorphan, midazolam, omeprazole, tolbutamide, diclofenac, theophylline, tolterodine
- MeSH terms
- Animals, Dogs, Drug Evaluation, Preclinical, Pharmaceutical Preparations, Humans, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prediction of metabolic drug clearance in humans:In vitro–in vivoextrapolationvsallometric scaling. https://app.cochat.ai/papers/10.1080/00498250600761662
- The paper
- Shiran, M. R., Proctor, N. J., Howgate, E. M., Rowland-Yeo, K., Tucker, G. T., & Rostami-Hodjegan, A. (2006). Prediction of metabolic drug clearance in humans:In vitro–in vivoextrapolationvsallometric scaling. Xenobiotica. https://doi.org/10.1080/00498250600761662
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.